Jennewein Biotechnologie GmbH enforces its patents in the field of human milk oligosaccharides against Nestlé in Germany
Nestlé offers its infant formula Beba Supreme which contains two human milk oligosaccharides – unique saccharides naturally occurring in human breast milk only – for sale in Germany. Pursuant to the findings of Jennewein Biotechnologie, Nestlé uses human milk oligosaccharides for the manufacturing of its infant formula that are produced by a process being protected - among other IP rights - by European Patents EP 2 896 628 and EP 3 131 912 (start of protection: January 22, 2020) which are thus infringed by Nestlé.
As Nestlé offers its infant food containing human milk oligosaccharides not just in Germany, Jennewein currently investigates measures against the assumed infringement of its corresponding foreign patents by the manufacturing of products such as Illuma, SMA, NAN and Gerber Good Start.
About HMOs:
Human milk oligosaccharides (HMOs) are complex sugar molecules that are only present in breast milk. Excluding water, they are the third most abundant constituent of human milk after fats and lactose. More than 200 structurally different HMOs have been identified. The most abundant HMO is 2′-fucosyllactose, which is produced by about 80% of all lactating mothers at concentrations of up to 3 g/L. Scientific studies have shown that HMOs, and 2′‑fucosyllactose in particular, have a positive impact on infant health and development. HMOs are prebiotics, i.e. they specifically promote the growth of beneficial microorganisms, and at the same time they inhibit the growth of pathogens by directly and indirectly preventing colonisation. Jennewein Biotechnologie launched 2′-fucosyllactose onto the global baby food market in 2015, and several infant milk formulas around the world now contain 2′-fucosyllactose (e.g. Abbott Similac).
About Jennewein Biotechnologie:
Jennewein Biotechnologie is a leading international industrial biotechnology company with a range of products in the field of complex oligosaccharides (HMOs) and rare monosaccharides.The company manufactures an extensive portfolio of innovative HMO products, such as 2′‑fucosyllactose, 3-fucosyllactose and lacto-N-tetraose. These rare sugars are used in the food industry (particularly infant milk formulas), the pharmaceutical industry, and the cosmetic industry. The manufacturing process involves state-of-the-art fermentation techniques. In 2015, the US Food and Drug Administration (FDA) granted Jennewein Biotechnologie a license to market 2′-fucosyllactose in the USA. This was followed in 2017 by The European Food Safety Authority (EFSA) under the Novel Food Regulation.
Press contact:
Dr. Bettina Gutierrez
Phone: +49 2224 98810 797
bettina.gutierrez@jennewein-biotech.de
Om Jennewein Biotechnologie GmbH
Jennewein Biotechnologie GmbHFølg pressemeldinger fra Jennewein Biotechnologie GmbH
Registrer deg med din e-postadresse under for å få de nyeste sakene fra Jennewein Biotechnologie GmbH på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra Jennewein Biotechnologie GmbH
Jennewein Biotechnologie sues Glycom for patent infringement in Denmark25.11.2019 10:45:37 CET | Pressemelding
Jennewein Biotechnologie develops fermentative processes for manufacturing of human milk oligosaccharides (HMOs) cost efficiently in an industrial scale since 2005 to make these special sugars available for affordably priced infant formula and other uses in food. Jennewein Biotechnologie was the first commercial vendor of HMOs, and brought the HMO 2’-fucosyllactose for the first time on the market in 2015. The Danish company Glycom A/S initially tried to chemically synthesize HMOs, but now imitates the path of biotechnological manufacturing of HMOs as pursued by Jennewein Biotechnologie from the beginning. “After Glycom failed for a decade to accomplish the chemical synthesis, as well as possible biotechnological attempts to produce HMOs at reasonable costs and in industrially relevant amounts, we became aware by Glycom’s recent EFSA and FSANZ filings that they are imitating Jennewein’s processes and infringing our intellectual property.” said Dr. Stefan Jennewein, CEO of Jennewein Bio
ADMINISTRATIVE LAW JUDGE ISSUES RULING IN PATENT DISPUTE CONCERNING 2’-FL PRODUCTION AND BETA-GALACTOSIDASE ACTIVITY12.9.2019 08:44:51 CEST | Pressemelding
(Rheinbreitbach): On September 09, 2019, Administrative Law Judge Cameron Elliot of the US International Trade Commission issued an Initial Determination finding that one of the bacterial strains used by Jennewein Biotechnologie to make 2’-fucosyllactose (2’-FL) infringes a patent owned by Glycosyn LLC. In the ITC Investigation, Complainant Glycosyn initially asserted two separate patents and a total of 68 patent claims. After factual discovery, Glycosyn withdrew one of the patents in its entirety and limited the other patent to 14 patent claims. Jennewein intends to appeal the ALJ’s Initial Determination, which is subject to review by the entire Commission. According to President and CEO Stefan Jennewein, “We are disappointed in the ALJ’s Initial Determination but continue to firmly believe that our process does not infringe any of Glycosyn’s patent claims. We intend to appealing the decision to the entire Commission.” Jennewein has already made arrangements for the use of alternative
Jennewein Biotechnologie and Yili Group join forces in China5.2.2019 10:00:00 CET | Pressemelding
Jennewein Biotechnologie and Yili Group join forces in China for microbiome research and human milk oligosaccharides to bring innovation to the largest baby food market